Skip to main content
رجوع
ACAD logo

ACADIA Pharmaceuticals Inc.

جودة البيانات: 100%
ACAD
NASDAQ Healthcare Biotechnology
KWD 20.99
▲ KWD 0.25 (1.21%)
القيمة السوقية: 3.58B
نطاق اليوم
KWD 20.94 KWD 21.51
نطاق 52 أسبوعًا
KWD 13.40 KWD 28.35
حجم التداول
1,255,209
متوسط 50 يوم / 200 يوم
KWD 24.03 / KWD 23.75
الإغلاق السابق
KWD 20.74

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E 9.2 0.4
P/B 2.9 2.9
ROE % 39.9 3.7
Net Margin % 36.5 3.9
Rev Growth 5Y % 22.0 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 34.200 +62.9%
Low: KWD 29.000 High: KWD 40.000
مكرر الربحية المستقبلي
46.6
ربحية السهم المستقبلية
KWD 0.450
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
1.2 B

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 2.601
KWD 2.414 – KWD 2.717
 1.8 B 12
FY2029 KWD 1.908
KWD 1.771 – KWD 1.993
 1.7 B 8
FY2028 KWD 1.574
KWD 0.591 – KWD 2.738
 1.6 B 14

النقاط الرئيسية

Revenue grew 21.97% annually over 5 years — strong growth
Earnings grew 72.66% over the past year
ROE of 39.89% indicates high profitability
Net margin of 36.49% shows strong profitability
Debt/Equity of 0.04 — conservative balance sheet
Generating 105.15M in free cash flow

النمو

Revenue Growth (5Y)
21.97%
Revenue (1Y)11.87%
Earnings (1Y)72.66%
FCF Growth (3Y)N/A

الجودة

Return on Equity
39.89%
ROIC6.14%
Net Margin36.49%
Op. Margin9.78%

الأمان

Debt / Equity
0.04
Current Ratio3.83
Interest Coverage0.00

التقييم

P/E Ratio
9.15
P/B Ratio2.92
EV/EBITDA32.95
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 11.87% Revenue Growth (3Y) 21.45%
Earnings Growth (1Y) 72.66% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 21.97% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1.07B Net Income (TTM) 391.00M
ROE 39.89% ROA 25.00%
Gross Margin 91.69% Operating Margin 9.78%
Net Margin 36.49% Free Cash Flow (TTM) 105.15M
ROIC 6.14% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.04 Current Ratio 3.83
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio 9.15 P/B Ratio 2.92
P/S Ratio 3.34 PEG Ratio 0.17
EV/EBITDA 32.95 Dividend Yield 0.00%
Market Cap 3.58B Enterprise Value 3.45B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.07B 957.80M 726.44M 517.24M 484.15M
Net Income 391.00M 226.45M -61.29M -215.98M -167.87M
EPS (Diluted) 2.29 1.36 -0.37 -1.34 -1.05
Gross Profit 982.51M 875.96M 680.71M 507.07M 465.00M
Operating Income 104.81M 230.79M -73.38M -223.60M -170.44M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.56B 1.19B 748.96M 587.81M 700.12M
Total Liabilities 336.81M 454.96M 317.20M 187.40M 159.23M
Shareholders' Equity 1.23B 732.79M 431.76M 400.41M 540.89M
Total Debt 52.19M 52.00M 57.21M 62.00M 64.43M
Cash & Equivalents 177.70M 319.59M 188.66M 114.85M 147.44M
Current Assets 1.06B 938.32M 616.13M 507.94M 617.82M
Current Liabilities 277.11M 394.87M 254.25M 125.63M 96.07M

درجات الاستراتيجيات

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Contrarian Investing (David Dreman)
#105 of 658
55
Growth Growth Investing (Philip Fisher)
#86 of 154
53
Value Value Investing (Warren Buffett)
#29 of 195
54
Custom Lower Risk
#69 of 136
45

النشاط الأخير

دخل Contrarian Investing (David Dreman)
Mar 24, 2026
دخل Growth Investing (Philip Fisher)
Mar 24, 2026
دخل Value Investing (Warren Buffett)
Mar 24, 2026
دخل Lower Risk
Mar 24, 2026